What the Options Market Tells Us About Amgen
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.
金融巨头在安进上做出了明显的看淡动作。我们对安进（纳斯达克：AMGN）期权历史的分析显示，有9笔异常交易。
Delving into the details, we found 11% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $169,060, and 6 were calls, valued at $411,757.
深入细节后，我们发现有11%的交易者看好，而55%的交易者表现出看淡趋势。在我们发现的所有交易中，有3笔看跌期权，价值为169,060美元，有6笔看涨期权，价值为411,757美元。
What's The Price Target?
价格目标是什么？
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $305.0 to $330.0 for Amgen during the past quarter.
分析这些合约的成交量和未平仓量，似乎大佬们一直在关注安进在过去的季度内的$305.0至$330.0的价格区间。
Volume & Open Interest Trends
成交量和未平仓量趋势
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Amgen's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Amgen's significant trades, within a strike price range of $305.0 to $330.0, over the past month.
仔细审视成交量和未平仓量，能为股票研究提供重要的见解。这些信息对于衡量在特定行使价格下，对安进期权的流动性和兴趣水平至关重要。以下是我们在去过的一个月中，以$305.0至$330.0行使价格区间内安进的看涨期权和看跌期权成交量和未平仓量趋势的快照。
Amgen Option Volume And Open Interest Over Last 30 Days
安进期权成交量和未平仓量在过去30天内的情况
Significant Options Trades Detected:
检测到重大期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | TRADE | NEUTRAL | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 262 |
| AMGN | CALL | TRADE | NEUTRAL | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 112 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $74.5K | 163 | 62 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $15.1 | $14.7 | $14.85 | $305.00 | $72.7K | 163 | 212 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $71.5K | 163 | 14 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看涨 | 交易 | 中立 | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 262 |
| AMGN | 看涨 | 交易 | 中立 | 08/16/24 | $15.15 | $14.8 | $14.95 | $305.00 | $74.7K | 163 | 112 |
| AMGN | 看涨 | 交易 | 看淡 | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $74.5K | 163 | 62 |
| AMGN | 看涨 | 交易 | 看淡 | 08/16/24 | $15.1 | $14.7 | $14.85 | $305.00 | $72.7K | 163 | 212 |
| AMGN | 看涨 | 交易 | 看淡 | 08/16/24 | $15.05 | $14.8 | $14.9 | $305.00 | $71.5千美元 | 163 | 14 |
About Amgen
关于安进
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安进是生物技术制药领域的领导者。旗舰药物包括增加红细胞计数的艾普毕与阿拉尼许、增强免疫系统的奈帕姆和奈乌细胞移植因子、以及针对炎症性疾病的恩布瑞尔和欧特兹拉。安进在2006年推出了首个癌症治疗药物Vectibix，并推出了增强骨密度的药物Prolia/Xgeva（于2010年获批）和Evenity（于2019年获批）。对Onyx的收购增强了该公司在治疗肿瘤领域的药物组合，其中包括Kyprolis。最近推出的药物包括Repatha（降低胆固醇）、Aimovig（缓解偏头痛）、Lumakras（治疗肺癌）以及Tezspire（治疗哮喘）。2023年Horizon收购带来了几种罕见疾病药物，其中包括治疗甲状腺眼病的Tepezza。安进还拥有不断增长的生物类似物组合。
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
在我们分析与安进相关的期权活动之后，我们将转向更仔细地研究公司自身的表现。
Where Is Amgen Standing Right Now?
目前安进的处境如何？
- Currently trading with a volume of 818,723, the AMGN's price is down by -0.29%, now at $310.12.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 30 days.
- 目前成交量为818,723，安进的价格下跌了-0.29%，现在为310.12美元。
- RSI读数表明该股目前可能接近超买水平。
- 预计收益发布还需30天。
Professional Analyst Ratings for Amgen
安进的专业分析师评级
2 market experts have recently issued ratings for this stock, with a consensus target price of $336.0.
2位市场专家最近对这支股票发表了评级，共识目标价为336.0美元。
- An analyst from RBC Capital has decided to maintain their Outperform rating on Amgen, which currently sits at a price target of $332.
- Maintaining their stance, an analyst from Argus Research continues to hold a Buy rating for Amgen, targeting a price of $340.
- 摩根资本（RBC Capital）的一位分析师决定维持对安进的跑赢大盘评级，目前的股价目标为332美元。
- 维持他们的立场，雅运股份分析师继续对安进持有买入评级，目标价为340美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期权交易具有更高的风险和潜在回报。精明的交易者通过不断学习、调整策略、监控多个因子和密切关注市场走势来管理这些风险。通过Benzinga Pro的实时提醒了解最新的安进期权交易。